Zogenix Says FDA Setbacks Acceptance Choice on Painkiller (ZGNX)

New York, NY -- (SBWIRE) -- 02/28/2013 -- Zogenix Inc. (NASDAQ:ZGNX) is a drug company commercializing and creating products for the treatment of neurological program conditions and discomfort. The Business's item Sumavel DosePro offers needle-free subcutaneous management of sumatriptan for the treatment of headaches and group frustration in a pre-filled, single-use distribution program. Its lead item applicant, Zohydro (hydrocodone bitartrate, formerly ZX002) is a 12-hour extended-release ingredients of hydrocodone without acetaminophen for the treatment of serious discomfort demanding opioid treatment.

Zogenix Inc. (NASDAQ:ZGNX) a drug organization that involves in the growth and commercialization of items for the therapy of neurological program conditions and discomfort is currently up (+43.79%) on 5,130,243 stocks exchanged after Zogenix Says FDA Setbacks Acceptance Choice on Painkiller. Zogenix, Inc. (NASDAQ:ZGNX) is currently up (+68.47%) from its latest 52-week low which has persuaded Increasing Inventory Review to add the stock to their NASDAQ Gainers Observe Record.

Just click Here to discover out what other Traders are saying about Zogenix (ZGNX)

DISCLAIMER
Neither PennyStocksUpdate.biz nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by PennyStocksUpdate.biz, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation.PennyStocksUpdate.biz makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through PennyStocksUpdate.biz. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned here in..

Contact:
PennyStocksUpdate.biz
info@pennystocksupdate.biz